SCAI: A Potential Drug Target Or Biomarker (G286205)

Target Name: SCAI

NCBI ID: G286205

SCAI

SCAI: A Potential Drug Target Or Biomarker

SCAI (C9orf126) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of cell signaling, and its levels have been linked to a number of diseases, including cancer. As a result, SCAI has generated a lot of interest as a potential drug target or biomarker.

SCAI is a member of the superfamily of cytoplasmic proteins, which are characterized by the presence of a cytoplasmic tail that is composed of a complex array of proteins. This family includes a number of well-known proteins, including the cytoplasmic protein T-cell antigen 4 (TCA4), which is also known as CD11b, and the cytoplasmic protein PDGF-R2, which is involved in cell signaling.

SCAI is expressed in a wide range of tissues throughout the body, including the brain, heart, and kidneys. It is highly expressed in the brain, where it is found in the cell nuclei and in the cytoplasm. It is also expressed in the heart, where it is found in the intercellular spaces of the cardiac muscle cells. SCAI is not expressed in the kidneys, which may be why it is considered as a potential drug target or biomarker for kidney disease.

SCAI plays a key role in cell signaling by regulating the levels of various signaling molecules, including tyrosine and chemokines. It does this by interacting with a number of different proteins, including the cytoplasmic protein TCA4 and the cytoplasmic protein PDGF-R2. TCA4 is a G protein-coupled receptor (GPCR), which is involved in cell signaling. It is expressed in many different tissues throughout the body, including the brain, heart, and kidneys. TCA4 is involved in the regulation of a wide range of physiological processes, including inflammation, pain, and sleep.

PDGF-R2 is a TGF-β superfamily protein, which is involved in cell signaling. It is expressed in many different tissues throughout the body, including the brain, heart, and kidneys. PDGF-R2 is involved in the regulation of a wide range of physiological processes, including cell growth, differentiation, and survival.

SCAI has been linked to a number of diseases, including cancer. For example, studies have shown that high levels of SCAI are associated with an increased risk of certain types of cancer, such as breast cancer and colon cancer. Additionally, SCAI has also been linked to a number of other diseases, including cardiovascular disease, neurodegenerative diseases, and autoimmune diseases.

As a result, SCAI has generated a lot of interest as a potential drug target or biomarker. Researchers are studying SCAI's role in cell signaling and are looking for ways to inhibit its activity. This may lead to the development of new treatments for a wide range of diseases. For example, studies have shown that inhibiting SCAI's activity can reduce the growth and spread of cancer cells. Additionally, inhibiting SCAI's activity has been shown to improve the function of the heart and kidneys in diseases such as heart failure and chronic kidney disease.

In conclusion, SCAI is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of cell signaling and has been linked to a number of diseases, including cancer. As a result, SCAI has generated a lot of interest as a potential drug target or biomarker, and its study is ongoing to determine its role in cell signaling and its potential as a treatment for various diseases.

Protein Name: Suppressor Of Cancer Cell Invasion

Functions: Tumor suppressor which functions to suppress MRTFA-induced SRF transcriptional activity. May function in the RHOA-DIAPH1 signal transduction pathway and regulate cell migration through transcriptional regulation of ITGB1

The "SCAI Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCAI comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets